InBrain Pharma, a start-up currently being created and incubated at Eurasanté, has won the University of Lille Foundation's call for expressions of interest, receiving €200,000 in funding.
It is developing a technology for the continuous administration of dopamine for patients with Parkinson's disease, originating from the University and Lille University Hospital and matured by SATT Nord.
M
Matthew Fisichella, future CEO, states that: " The foundation's support enables the creation of a new company. Our solution will improve the quality of life for patients with Parkinson's disease, just as insulin pumps have improved the treatment of diabetes.